A high-throughput drug screening strategy for detecting rhodopsin P23H mutant rescue and degradation

Investigative Ophthalmology and Visual Science

Volumn 56, Issue 4, 2015, Pages 2553-2567

  Chen, Yuanyuan ^a   Tang, Hong ^b   Seibel, William ^b,d   Papoian, Ruben ^b   Li, Xiaoyu ^a   Lambert, Nevin A ^c   Palczewski, Krzysztof ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c MEDICAL COLLEGE OF GEORGIA   (United States)

^d CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

GPCR; Misfolded protein; Ocular pharmacology; Phototransduction; References; Retinal degeneration; Rhodopsin; Rod photoreceptors

Indexed keywords

BETA GALACTOSIDASE; OPSIN; RHODOPSIN; MUTANT PROTEIN;

ALPHA IMMUNOASSAY; ARTICLE; BIOLUMINESCENCE RESONANCE ENERGY TRANSFER; CONTROLLED STUDY; DOT HYBRIDIZATION; GENE TRANSLOCATION; GLYCOSYLATION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IMAGE ANALYSIS; IMMUNOASSAY; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; LUCIFERASE ASSAY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; RENILLA LUCIFERASE ACTIVITY ASSAY; ANIMAL; CELL CULTURE; DISEASE MODEL; DRUG SCREENING; GENETICS; METABOLISM; MUTATION; PATHOLOGY; PHOTORECEPTOR CELL; PROCEDURES; RETINITIS PIGMENTOSA;

ANIMALS; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; IMMUNOBLOTTING; MICE; MUTANT PROTEINS; MUTATION; PHOTORECEPTOR CELLS; RETINITIS PIGMENTOSA; RHODOPSIN;

EID: 84939630191     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.14-16298     Document Type: Article

References (95)

1. Reddy AS, Zhang S. Polypharmacology: drug discovery for the future. Expert Rev Clin Pharmacol. 2013;6:41-47.
2. Carrieri A, Perez-Nueno VI, Lentini G, Ritchie DW. Recent trends and future prospects in computational GPCR drug discovery: from virtual screening to polypharmacology. Curr Top Med Chem. 2013;13:1069-1097.
3. Zhao S, Iyengar R. Systems pharmacology: network analysis to identify multiscale mechanisms of drug action. Annu Rev Pharmacol Toxicol. 2012;52:505-521.
4. Kenakin TP. Cellular assays as portals to seven-transmembrane receptor-based drug discovery. Nat Rev Drug Discov. 2009;8: 617-626.
5. Vanni S, Rothlisberger U. A closer look into G protein coupled receptor activation: x-ray crystallography and long-scale molecular dynamics simulations. Curr Med Chem. 2012;19: 1135-1145.
6. Palczewski K. G protein-coupled receptor rhodopsin. Annu Rev Biochem. 2006;75:743-767.
7. Kiser PD, Golczak M, Palczewski K. Chemistry of the retinoid (visual) cycle. Chem Rev. 2014;114:194-232.
8. Ballesteros J, Palczewski K. G protein-coupled receptor drug discovery: implications from the crystal structure of rhodopsin. Curr Opin Drug Discov Devel. 2001;4:561-574.
9. Filipek S, Stenkamp RE, Teller DC, Palczewski K. G protein-coupled receptor rhodopsin: a prospectus. Annu Rev Physiol. 2003;65:851-879.
10. Palczewski K. Retinoids for treatment of retinal diseases. Trends Pharmacol Sci. 2010;31:284-295.
11. Sakami S, Kolesnikov AV, Kefalov VJ, Palczewski K. P23H opsin knock-in mice reveal a novel step in retinal rod disc morphogenesis. Hum Mol Genet. 2014;23:1723-1741.
12. Chiang WC, Kroeger H, Sakami S, et al. Robust endoplasmic reticulum-associated degradation of rhodopsin precedes retinal degeneration [published online ahead of print October 2, 2014]. Mol Neurobiol. doi:10.1007/s12035-014-8881-8.
13. Chen Y, Jastrzebska B, Cao P, et al. Inherent instability of the retinitis pigmentosa P23H mutant opsin. J Biol Chem. 2014; 289:9288-9303.
14. Aguila M, Bevilacqua D, McCulley C, et al. Hsp90 inhibition protects against inherited retinal degeneration. Hum Mol Genet. 2014;23:2164-2175.
15. Lee DC, Vazquez-Chona FR, Ferrell WD, et al. Dysmorphic photoreceptors in a P23H mutant rhodopsin model of retinitis pigmentosa are metabolically active and capable of regenerating to reverse retinal degeneration. J Neurosci. 2012;32: 2121-2128.
16. Gorbatyuk MS, Gorbatyuk OS, LaVail MM, Lin JH, Hauswirth WW, Lewin AS. Functional rescue of P23H rhodopsin photoreceptors by gene delivery. Adv Exp Med Biol. 2012; 723:191-197.
17. Griciuc A, Aron L, Roux MJ, Klein R, Giangrande A, Ueffing M. Inactivation of VCP/ter94 suppresses retinal pathology caused by misfolded rhodopsin in Drosophila. PLoS Genet. 2010;6.
18. Gorbatyuk MS, Knox T, LaVail MM, et al. Restoration of visual function in P23H rhodopsin transgenic rats by gene delivery of BiP/Grp78. Proc Natl Acad Sci U S A. 2010;107:5961-5966.
19. Tam BM, Moritz OL. Dark rearing rescues P23H rhodopsin-induced retinal degeneration in a transgenic Xenopus laevis model of retinitis pigmentosa: a chromophore-dependent mechanism characterized by production of N-terminally truncated mutant rhodopsin. J Neurosci. 2007;27:9043-9053.
20. Noorwez SM, Malhotra R, McDowell JH, Smith KA, Krebs MP, Kaushal S. Retinoids assist the cellular folding of the autosomal dominant retinitis pigmentosa opsin mutant P23H. J Biol Chem. 2004;279:16278-16284.
21. Sakami S, Maeda T, Bereta G, et al. Probing mechanisms of photoreceptor degeneration in a new mouse model of the common form of autosomal dominant retinitis pigmentosa due to P23H opsin mutations. J Biol Chem. 2011;286:10551-10567.
22. Liang Y, Fotiadis D, Maeda T, et al. Rhodopsin signaling and organization in heterozygote rhodopsin knockout mice. J Biol Chem. 2004;279:48189-48196.
23. Baell J, Walters MA. Chemistry: chemical con artists foil drug discovery. Nature. 2014;513:481-483.
24. Soares JG, Fiorani M, Araujo EA, et al. Cone photopigment variations in Cebus apella monkeys evidenced by electroretinogram measurements and genetic analysis. Vision Res. 2010; 50:99-106.
25. Lan TH, Liu Q, Li C, Wu G, Lambert NA. Sensitive and high resolution localization and tracking of membrane proteins in live cells with BRET. Traffic. 2012;13:1450-1456.
26. Hamdan FF, Audet M, Garneau P, Pelletier J, Bouvier M. High-throughput screening of G protein-coupled receptor antagonists using a bioluminescence resonance energy transfer 1based beta-arrestin2 recruitment assay. J Biomol Screen. 2005; 10:463-475.
27. Palczewski K, Kumasaka T, Hori T, et al. Crystal structure of rhodopsin: a G protein-coupled receptor. Science. 2000;289: 739-745.
28. Zhang JH, Chung TD, Oldenburg KRA. Simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen. 1999;4:67-73.
29. Alegria-Schaffer A. Western blotting using chemiluminescent substrates. Methods Enzymol. 2014;541:251-259.
30. Saliba RS, Munro PM, Luthert PJ, Cheetham ME. The cellular fate of mutant rhodopsin: quality control, degradation and aggresome formation. J Cell Sci. 2002;115:2907-2918.
31. Ohgane K, Dodo K, Hashimoto Y. Retinobenzaldehydes as proper-trafficking inducers of folding-defective P23H rhodopsin mutant responsible for retinitis pigmentosa. Bioorg Med Chem. 2010;18:7022-7028.
32. Auld DS, Southall NT, Jadhav A, et al. Characterization of chemical libraries for luciferase inhibitory activity. J Med Chem. 2008;51:2372-2386.
33. Hammer MM, Wehrman TS, Blau HM. A novel enzyme complementation-based assay for monitoring G-protein-coupled receptor internalization. FASEB J. 2007;21:3827-3834.
34. Chen Y, Tang H, Seibel W, et al. Identification and characterization of novel inhibitors of mammalian aspartyl aminopeptidase. Mol Pharmacol. 2014;86:231-242.
35. Wang J, Xie X. Development of a quantitative, cell-based, high-content screening assay for epidermal growth factor receptor modulators. Acta Pharmacol Sin. 2007;28:1698-1704.
36. Singh S, Carpenter AE, Genovesio A. Increasing the content of high-content screening: an overview. J Biomol Screen. 2014; 19:640-650.
37. Chen L, Jin L, Zhou N. An update of novel screening methods for GPCR in drug discovery. Expert Opin Drug Discov. 2012;7: 791-806.
38. Agler M, Prack M, Zhu Y, et al. A high-content glucocorticoid receptor translocation assay for compound mechanism-ofaction evaluation. J Biomol Screen. 2007;12:1029-1041.
39. Garippa RJ, Hoffman AF, Gradl G, Kirsch A. High-throughput confocal microscopy for beta-arrestin-green fluorescent protein translocation G protein-coupled receptor assays using the Evotec Opera. Methods Enzymol. 2006;414:99-120.
40. Sung CH, Schneider BG, Agarwal N, Papermaster DS, Nathans J. Functional heterogeneity of mutant rhodopsins responsible for autosomal dominant retinitis pigmentosa. Proc Natl Acad Sci U S A. 1991;88:8840-8844.
41. Eglen RM, Reisine T. Photoproteins: important new tools in drug discovery. Assay Drug Dev Technol. 2008;6:659-671.
42. Eglen RM, Gilchrist A, Reisine T. The use of immortalized cell lines in GPCR screening: the good, bad and ugly. Comb Chem High Throughput Screen. 2008;11:560-565.
43. Baell JB, Holloway GA. New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. J Med Chem. 2010;53:2719-2740.
44. Hoelder S, Clarke PA, Workman P. Discovery of small molecule cancer drugs: successes, challenges and opportunities. Mol Oncol. 2012;6:155-176.
45. Hartong DT, Berson EL, Dryja TP. Retinitis pigmentosa. Lancet. 2006;368:1795-1809.
46. Sahel J, Bonnel S, Mrejen S, Paques M. Retinitis pigmentosa and other dystrophies. Dev Ophthalmol. 2010;47:160-167.
47. Zhang N, Kolesnikov AV, Jastrzebska B, et al. Autosomal recessive retinitis pigmentosa E150K opsin mice exhibit photoreceptor disorganization. J Clin Invest. 2013;123:121-137.
48. Sung CH, Davenport CM, Hennessey JC, et al. Rhodopsin mutations in autosomal dominant retinitis pigmentosa. Proc Natl Acad Sci U S A. 1991;88:6481-6485.
49. Jacobson SG, Kemp CM, Sung CH, Nathans J. Retinal function and rhodopsin levels in autosomal dominant retinitis pigmentosa with rhodopsin mutations. Am J Ophthalmol. 1991;112: 256-271.
50. Mendes HF, van der Spuy J, Chapple JP, Cheetham ME. Mechanisms of cell death in rhodopsin retinitis pigmentosa: implications for therapy. Trends Mol Med. 2005;11:177-185.
51. Nakao T, Tsujikawa M, Notomi S, Ikeda Y, Nishida K. The role of mislocalized phototransduction in photoreceptor cell death of retinitis pigmentosa. PLoS One. 2012;7:e32472.
52. Berson EL. Retinitis pigmentosa. The Friedenwald Lecture. Invest Ophthalmol Vis Sci. 1993;34:1659-1676.
53. Berson EL. Retinitis pigmentosa: unfolding its mystery. Proc Natl Acad Sci U S A. 1996;93:4526-4528.
54. Berson EL, Rosner B, Sandberg MA, Dryja TP. Ocular findings in patients with autosomal dominant retinitis pigmentosa and a rhodopsin gene defect (Pro-23-His). Arch Ophthalmol. 1991; 109:92-101.
55. Palczewski K. Chemistry and biology of vision. J Biol Chem. 2012;287:1612-1619.
56. Kevany BM, Palczewski K. Phagocytosis of retinal rod and cone photoreceptors. Physiology (Bethesda). 2010;25:8-15.
57. Humphries MM, Rancourt D, Farrar GJ, et al. Retinopathy induced in mice by targeted disruption of the rhodopsin gene. Nat Genet. 1997;15:216-219.
58. Lem J, Krasnoperova NV, Calvert PD, et al. Morphological, physiological, and biochemical changes in rhodopsin knock-out mice. Proc Natl Acad Sci U S A. 1999;96:736-741.
59. Rosenfeld PJ, Cowley GS, McGee TL, Sandberg MA, Berson EL, Dryja TP. A null mutation in the rhodopsin gene causes rod photoreceptor dysfunction and autosomal recessive retinitis pigmentosa. Nat Genet. 1992;1:209-213.
60. Oprian DD. Molecular determinants of spectral properties and signal transduction in the visual pigments. Curr Opin Neurobiol. 1992;2:428-432.
61. Kaushal S, Khorana HG. Structure and function in rhodopsin. 7. Point mutations associated with autosomal dominant retinitis pigmentosa. Biochemistry. 1994;33:6121-6128.
62. Olsson JE, Gordon JW, Pawlyk BS, et al. Transgenic mice with a rhodopsin mutation (Pro23His): a mouse model of autosomal dominant retinitis pigmentosa. Neuron. 1992;9:815-830.
63. Naash MI, Hollyfield JG, al-Ubaidi MR, Baehr W. Simulation of human autosomal dominant retinitis pigmentosa in transgenic mice expressing a mutated murine opsin gene. Proc Natl Acad Sci U S A. 1993;90:5499-5503.
64. Roof DJ, Adamian M, Hayes A. Rhodopsin accumulation at abnormal sites in retinas of mice with a human P23H rhodopsin transgene. Invest Ophthalmol Vis Sci. 1994;35: 4049-4062.
65. Lewin AS, Drenser KA, Hauswirth WW, et al. Ribozyme rescue of photoreceptor cells in a transgenic rat model of autosomal dominant retinitis pigmentosa. Nat Med. 1998;4:967-971.
66. LaVail MM, Yasumura D, Matthes MT, et al. Ribozyme rescue of photoreceptor cells in P23H transgenic rats: long-term survival and late-stage therapy. Proc Natl Acad Sci U S A. 2000;97: 11488-11493.
67. Petters RM, Alexander CA, Wells KD, et al. Genetically engineered large animal model for studying cone photoreceptor survival and degeneration in retinitis pigmentosa. Nat Biotechnol. 1997;15:965-970.
68. Kosmaoglou M, Schwarz N, Bett JS, Cheetham ME. Molecular chaperones and photoreceptor function. Prog Retin Eye Res. 2008;27:434-449.
69. Haeri M, Knox BE. Rhodopsin mutant P23H destabilizes rod photoreceptor disk membranes. PLoS One. 2012;7:e30101.
70. Tam BM, Moritz OL. Characterization of rhodopsin P23H-induced retinal degeneration in a Xenopus laevis model of retinitis pigmentosa. Invest Ophthalmol Vis Sci. 2006;47: 3234-3241.
71. Zhang R, Oglesby E, Marsh-Armstrong N. Xenopus laevis P23H rhodopsin transgene causes rod photoreceptor degeneration that is more severe in the ventral retina and is modulated by light. Exp Eye Res. 2008;86:612-621.
72. Noorwez SM, Kuksa V, Imanishi Y, et al. Pharmacological chaperone-mediated in vivo folding and stabilization of the P23H-opsin mutant associated with autosomal dominant retinitis pigmentosa. J Biol Chem. 2003;278:14442-14450.
73. Scherer LJ, Rossi JJ. Approaches for the sequence-specific knockdown of mRNA. Nat Biotechnol. 2003;21:1457-1465.
74. Drenser KA, Timmers AM, Hauswirth WW, Lewin AS. Ribozyme-targeted destruction of RNA associated with autosomal-dominant retinitis pigmentosa. Invest Ophthalmol Vis Sci. 1998;39:681-689.
75. Mao H, Gorbatyuk MS, Rossmiller B, Hauswirth WW, Lewin AS. Long-term rescue of retinal structure and function by rhodopsin RNA replacement with a single adeno-associated viral vector in P23H RHO transgenic mice. Hum Gene Ther. 2012;23:356-366.
76. Mao H, James T Jr, Schwein A, et al. AAV delivery of wild-type rhodopsin preserves retinal function in a mouse model of autosomal dominant retinitis pigmentosa. Hum Gene Ther. 2011;22:567-575.
77. Frederick JM, Krasnoperova NV, Hoffmann K, et al. Mutant rhodopsin transgene expression on a null background. Invest Ophthalmol Vis Sci. 2001;42:826-833.
78. Rossmiller B, Mao H, Lewin AS. Gene therapy in animal models of autosomal dominant retinitis pigmentosa. Mol Vis. 2012;18: 2479-2496.
79. Berson EL, Rosner B, Sandberg MA, et al. Further evaluation of docosahexaenoic acid in patients with retinitis pigmentosa receiving vitamin A treatment: subgroup analyses. Arch Ophthalmol. 2004;122:1306-1314.
80. Berson EL, Rosner B, Sandberg MA, et al. Clinical trial of docosahexaenoic acid in patients with retinitis pigmentosa receiving vitamin A treatment. Arch Ophthalmol. 2004;122: 1297-1305.
81. Noorwez SM, Ostrov DA, McDowell JH, Krebs MP, Kaushal S. A high-throughput screening method for small-molecule pharmacologic chaperones of misfolded rhodopsin. Invest Ophthalmol Vis Sci. 2008;49:3224-3230.
82. Krebs MP, Holden DC, Joshi P, Clark CL III, Lee AH, Kaushal S. Molecular mechanisms of rhodopsin retinitis pigmentosa and the efficacy of pharmacological rescue. J Mol Biol. 2010;395: 1063-1078.
83. Tam LC, Kiang AS, Campbell M, et al. Prevention of autosomal dominant retinitis pigmentosa by systemic drug therapy targeting heat shock protein 90 (Hsp90). Hum Mol Genet. 2010;19:4421-4436.
84. Mendes HF, Cheetham ME. Pharmacological manipulation of gain-of-function and dominant-negative mechanisms in rhodopsin retinitis pigmentosa. Hum Mol Genet. 2008;17:3043-3054.
85. Chalmel F, Leveillard T, Jaillard C, et al. Rod-derived Cone Viability Factor-2 is a novel bifunctional-thioredoxin-like protein with therapeutic potential. BMC Mol Biol. 2007;8:74.
86. Leveillard T, Mohand-Said S, Lorentz O, et al. Identification and characterization of rod-derived cone viability factor. Nat Genet. 2004;36:755-759.
87. Yang Y, Mohand-Said S, Danan A, et al. Functional cone rescue by RdCVF protein in a dominant model of retinitis pigmentosa. Mol Ther. 2009;17:787-795.
88. Zhu Q, Sun W, Okano K, et al. Sponge transgenic mouse model reveals important roles for the microRNA-183 (miR-183)/96/ 182 cluster in postmitotic photoreceptors of the retina. J Biol Chem. 2011;286:31749-31760.
89. Georgiadis A, Tschernutter M, Bainbridge JW, et al. AAV- mediated knockdown of peripherin-2 in vivo using miRNA-based hairpins. Gene Ther. 2010;17:486-493.
90. Zhang L, Wang T, Wright AF, et al. A microdeletion in Xp11.3 accounts for co-segregation of retinitis pigmentosa and mental retardation in a large kindred. Am J Med Genet A. 2006;140: 349-357.
91. Yang Y, Mohand-Said S, Leveillard T, Fontaine V, Simonutti M, Sahel JA. Transplantation of photoreceptor and total neural retina preserves cone function in P23H rhodopsin transgenic rat. PLoS One. 2010;5:e13469.
92. Punzo C, Xiong W, Cepko CL. Loss of daylight vision in retinal degeneration: are oxidative stress and metabolic dysregulation to blame? J Biol Chem. 2012;287:1642-1648.
93. Tam BM, Qazalbash A, Lee HC, Moritz OL. The dependence of retinal degeneration caused by the rhodopsin P23H mutation on light exposure and vitamin a deprivation. Invest Ophthalmol Vis Sci. 2010;51:1327-1334.
94. Montana CL, Kolesnikov AV, Shen SQ, Myers CA, Kefalov VJ, Corbo JC. Reprogramming of adult rod photoreceptors prevents retinal degeneration. Proc Natl Acad Sci U S A. 2013;110:1732-1737.
95. Fernandez-Sanchez L, Lax P, Isiegas C, et al. Proinsulin slows retinal degeneration and vision loss in the P23H rat model of retinitis pigmentosa. Hum Gene Ther. 2012;23:1290-1300.